Abstract
Saxagliptin is one of the four antidiabetic agents from the group dipeptidyl peptidase-4 inhibitors used in our country. New studies have significantly expanded its indications.
Today it is used as part of a two-drug combination with metformin (including the potential use in fixed combination), and also in two-drug combinations with sulfonylureas or thiazolindiones. It is also administered as part of three-drug combination oral treatment with metformin and sulfonylureas as well as in two- or three-drug combination treament with insulin and metformin, or without metformin.
All these combinations have the advantage of minimum risk of hypoglycaemia and good tolerance. An important aspect is the possible use in kidney and liver insufficiency.
It thus follows from the above that saxagliptin is important drug used today in the treatment of adult patients with type 2 diabetes, including those in the eldest population and patients with diabetic complications.